Trial abstract · §3
GSH-PD-PH2 — results
Primary endpoint, absolute and relative effect where derivable, and harms as reported.
§3Results
§3.1Primary endpoint
Table 3. Primary endpoint as reported.
| Endpoint | Result as reported | Certainty |
|---|---|---|
| Change in the Unified Parkinson’s Disease Rating Scale after intranasal administration | No significant difference from placebo | Low |
| Reproduced from the published report. Where the report states a confidence interval the Institute reproduces it; where it does not, none is constructed. | ||
§3.2Endpoint hierarchy
§3.3Harms as reported
Table 5. Adverse events for Glutathione from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.
| Event | Active, % | Comparator, % | Source trial |
|---|---|---|---|
| Injection-site reaction | — | — | Reported |
| Severe adverse events with unlicensed intravenous skin-lightening use | — | — | Regulatory authorities in several jurisdictions have issued warnings following reports of severe reactions including Stevens-Johnson syndrome, renal impairment and thyroid dysfunction associated with high-dose intravenous glutathione marketed for skin lightening |
| Bronchospasm with nebulised administration | — | — | Reported in people with asthma |
Compound Evidence Institute · CEI-TR-0128/3 · https://compoundevidence.com/trials/gsh-pd-ph2/results/ · retrieved 30 July 2026